MDGL logo

Madrigal Pharmaceuticals Inc. (MDGL)

$423.96

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on MDGL

Market cap

$9.85B

EPS

-12.87

P/E ratio

--

Price to sales

8.49

Dividend yield

--

Beta

-0.993388

Price on MDGL

Previous close

$427.39

Today's open

$424.08

Day's range

$418.11 - $429.94

52 week range

$353.54 - $615

Profile about MDGL

CEO

Bill Sibold

Employees

915

Headquarters

West Conshohocken, PA

Exchange

Nasdaq Global Select

Shares outstanding

23229561

Issue type

Common Stock

MDGL industries and sectors

Healthcare

Biotechnology & Life Sciences

News on MDGL

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • 12 hours ago

news preview

Kaplan Fox Notifies Madrigal Pharmaceuticals, Inc. (MDGL) Investors of a Securities Investigation into the Company

New York, New York--(Newsfile Corp. - November 17, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.

news source

Newsfile Corp • 15 hours ago

news preview

Kaplan Fox Reminds Investors of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) to Contact the Firm Regarding an Investigation of Potential Securities Law Violations

NEW YORK, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.

news source

GlobeNewsWire • Nov 16, 2026

news preview

Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (MDGL) on Behalf of Investors for Potential Securities Law Violations

New York, New York--(Newsfile Corp. - November 16, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.

news source

Newsfile Corp • Nov 16, 2026

news preview

MDGL Investigation Notification: Madrigal Pharmaceuticals, Inc. Investors are Encouraged to Contact Kessler Topaz Meltzer & Check, LLP

RADNOR, Pa., Nov. 14, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Madrigal Pharmaceuticals, Inc. (“Madrigal”) (NASDAQ: MDGL) on behalf of investors who purchased or acquired Madrigal securities and experienced significant financial losses.

news source

GlobeNewsWire • Nov 14, 2026

news preview

Kaplan Fox is Investigating Madrigal Pharmaceuticals, Inc. (MDGL) and Encourages Investors Who Suffered Losses to Contact the Firm

New York, New York--(Newsfile Corp. - November 13, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.

news source

Newsfile Corp • Nov 13, 2026

news preview

Kaplan Fox is Investigating Claims on Behalf of Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) Investors for Potential Securities Law Violations

NEW YORK, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. (“Madrigal” or the “Company”) (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.

news source

GlobeNewsWire • Nov 13, 2026

news preview

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

CONSHOHOCKEN, Pa., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences:

news source

GlobeNewsWire • Nov 13, 2026

news preview

Kaplan Fox & Kilsheimer LLP Announces an Investigation into Madrigal Pharmaceuticals, Inc. (MDGL) for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - November 12, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.

news source

Newsfile Corp • Nov 12, 2026

news preview

Kaplan Fox Encourages Investors of Madrigal Pharmaceuticals, Inc. (MDGL) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation

New York, New York--(Newsfile Corp. - November 11, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations by Madrigal Pharmaceuticals, Inc. ("Madrigal" or the "Company") (NASDAQ: MDGL). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Madrigal investor and have suffered losses, or if you have information that could assist in the Madrigal investigation, you may CLICK HERE to contact us.

news source

Newsfile Corp • Nov 11, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Madrigal Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Madrigal Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in MDGL on M1